<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="P0b002ee18038c0d2">
<name type="corporate">
 <namePart>United States Government Publishing Office</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
  <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
</role>
 <role>
  <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
  <roleTerm authority="marcrelator" type="code">dst</roleTerm>
</role>
</name>
<name type="corporate">
 <namePart>United States</namePart>
 <namePart>Government Accountability Office</namePart>
 <namePart>National Security and International Affairs Division</namePart>
 <role>
  <roleTerm authority="marcrelator" type="text">author</roleTerm>
  <roleTerm authority="marcrelator" type="code">aut</roleTerm>
</role>
 <description>Government Organization</description>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">government publication</genre>
<language>
 <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<extension>
 <collectionCode>GAOREPORTS</collectionCode>
 <category>Legislative Agency Publications</category>
 <waisDatabaseName>gao</waisDatabaseName>
 <branch>legislative</branch>
 <dateIngested>2010-08-12</dateIngested>
</extension>
<originInfo>
 <publisher>U.S. Government Printing Office</publisher>
 <dateIssued encoding="w3cdtf">1999-03-16</dateIssued>
 <issuance>monographic</issuance>
</originInfo>
<physicalDescription>
 <note type="source content type">deposited</note>
 <digitalOrigin>born digital</digitalOrigin>
 <extent>16 p.</extent>
</physicalDescription>
<classification authority="sudocs">GA 1.13:T-NSIAD-99-112</classification>
<identifier type="uri">https://www.govinfo.gov/app/details/GAOREPORTS-T-NSIAD-99-112</identifier>
<identifier type="local">P0b002ee18038c0d2</identifier>
<identifier type="former package identifier">f:ns99112t</identifier>
<recordInfo>
 <recordContentSource authority="marcorg">DGPO</recordContentSource>
 <recordCreationDate encoding="w3cdtf">2010-08-12</recordCreationDate>
 <recordChangeDate encoding="w3cdtf">2011-03-28</recordChangeDate>
 <recordIdentifier source="DGPO">GAOREPORTS-T-NSIAD-99-112</recordIdentifier>
 <recordOrigin>machine generated</recordOrigin>
 <languageOfCataloging>
  <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</languageOfCataloging>
</recordInfo>
<accessCondition type="GPO scope determination">fdlp</accessCondition>
<extension>
 <docClass>REPORT</docClass>
 <accessId>GAOREPORTS-T-NSIAD-99-112</accessId>
 <reportNumber>T-NSIAD-99-112</reportNumber>
 <subject>Interagency relations</subject>
 <subject>Terrorism</subject>
 <subject>Strategic planning</subject>
 <subject>Emergency preparedness</subject>
 <subject>Explosives</subject>
 <subject>Domestic intelligence</subject>
 <subject>Biological warfare</subject>
 <subject>Chemical warfare</subject>
 <type>Testimony</type>
 <seriesAbbrev>NSIAD</seriesAbbrev>
 <accountNo>S99112</accountNo>
 <law congress="105" isPrivate="false" number="277"></law>
</extension>
<titleInfo>
 <title>Combating Terrorism: Observations on Biological Terrorism and Public Health Initiatives</title>
</titleInfo>
<abstract>Pursuant to a congressional request, GAO discussed its ongoing work and
preliminary observations on the biological terrorist threat and some
aspects of the Department of Health and Human Services&apos; (HHS)
bioterrorism initiative, focusing on: (1) intelligence agencies&apos;
judgments about the threat of terrorism; (2) the importance and benefits
of threat and risk assessments to provide a sound basis for targeting
the nation&apos;s investments in combating terrorism; (3) preliminary
observations from GAO&apos;s ongoing work on the science behind the
biological and chemical terrorist threat, with some focus on biological
agents; and (4) overall observations on public health initiatives that
deal with a new national pharmaceutical stockpile and the basis for
selecting items to research, produce, procure, and stockpile for
civilian defense against terrorism.&lt;p/&gt;GAO noted that: (1) the U.S. intelligence community continuously
assesses both the foreign-origin and the domestic terrorist threat to
the United States and notes that, overall, conventional explosives and
firearms continue to be the weapons of choice for terrorists; (2)
terrorists are less likely to use biological and chemical weapons than
conventional explosives, at least partly because they are difficult to
weaponize and the results are unpredictable; (3) however, some groups
and individuals of concern are showing interest in biological and
chemical agents; (4) the possibility that terrorists may use biological
and chemical materials may increase over the next decade, according to
intelligence agencies; (5) while biological and chemical terrorism is
still an emerging threat, many agencies have initiated programs and
activities--with Congress&apos; support and funding--to combat and prepare
for this threat; (6) GAO has previously reported on the value of a new,
post-Cold War approach of using sound threat and risk assessments
performed by a multidisciplinary team of experts for focusing programs
and investments to combat terrorism; (7) without such assessments using
sound inputs and a multidisciplinary team of experts, there is little or
no assurance that programs and spending are focused in the right areas
in the right amounts; (8) GAO is looking into the scientific and
practical feasibility of a terrorist or terrorist group improvising a
biological weapon or device outside a state-run laboratory and program,
successfully and effectively disseminating biological agents, and
causing mass casualties; (9) much of the information obtained is
sensitive, classified, and in the early stages of evaluation; (10)
overall, there are serious challenges at various stages of the process
for a terrorist group or individual to successfully cause mass
casualties with an improvised biological or chemical weapon or device;
(11) for its part of domestic preparedness initiatives for combating
terrorism, HHS received about $160 million in fiscal year (FY) 1999;
(12) these funds are intended for a variety of related preparedness
efforts, including research and development and a new national stockpile
for pharmaceuticals, millions of doses of vaccines for smallpox and
anthrax, antidotes for chemical agents, and other items; and (13) for FY
2000, HHS has requested $230 million for public health initiatives for
dealing with bioterrorism.</abstract>
<location>
 <url displayLabel="HTML rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-T-NSIAD-99-112/html/GAOREPORTS-T-NSIAD-99-112.htm</url>
 <url displayLabel="PDF rendition" access="raw object">https://www.govinfo.gov/content/pkg/GAOREPORTS-T-NSIAD-99-112/pdf/GAOREPORTS-T-NSIAD-99-112.pdf</url>
</location>
<identifier type="preferred citation">GAO/T-NSIAD-99-112</identifier>
<location>
 <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/GAOREPORTS-T-NSIAD-99-112</url>
</location>
<note>Testimony</note>
<extension>
 <searchTitle>GAO/T-NSIAD-99-112; Combating Terrorism: Observations on Biological Terrorism and Public Health Initiatives;
            </searchTitle>
</extension>
<subject>
 <topic>Interagency relations</topic>
 <topic>Terrorism</topic>
 <topic>Strategic planning</topic>
 <topic>Emergency preparedness</topic>
 <topic>Explosives</topic>
 <topic>Domestic intelligence</topic>
 <topic>Biological warfare</topic>
 <topic>Chemical warfare</topic>
</subject>
<relatedItem type="isReferencedBy">
 <titleInfo>
  <title>United States Public Law 277 (105th Congress)</title>
</titleInfo>
 <identifier type="public law citation">Public Law 105-277</identifier>
</relatedItem>
</mods>